VENuS Trial
The trial’s main limitation is that 28 weeks may be insufficient to fully assess long-term structural progression. The VENuS trial evaluates vunakizumab versus placebo in symptomatic erosive hand osteoarthritis.
1 sources - 5 claims
The trial’s main limitation is that 28 weeks may be insufficient to fully assess long-term structural progression. The VENuS trial evaluates vunakizumab versus placebo in symptomatic erosive hand osteoarthritis.